doi: 10.1002/pst.433 44 KaplanELMeierP
V.KellyB.RechsteinerK.KarpiakJ.BetzR
We observed an initial blunted response at time points 10 ( BrAC Control = 0.037, BrAC GLP-1RA = 0.021, t(113) = 3.21, p = 0.014), 15 ( BrAC Control = 0.028, BrAC GLP-1RA = 0.013, t(113) = 2.98, p = 0.028) and 20 min (BrAC Control = 0.037, BrAC GLP-1RA = 0.017, t(113) = 3.87, p = 0.001) in the GLP-1RA group as compared to the control group
More Americans are turning to GLP-1 drugs, such as Ozempic or Mounjaro, for weight loss help, according to a RAND report released earlier this monthmeaning 11.8% of U.S
BMI Insights: An overwhelming majority of users have obesity
An oral version of these drugswhich are known as glucagon-like peptide 1 (GLP-1) receptor agonistscould be more accessible and would come without the inconvenience, pain or medical waste of shots